FGFR3 and central nervous system cancer: Amplifications and mutations of PDGFRA, KIT and KDR were found in 8-15% of RMPAhigh gliomas, followed by EPHB3 (7.7%), FGFR1 (5.9%), FGFR3 (5.9%) and MET (4.1%) (Supplementary Table S6).